With the expiry of multiple biologic patents fast approaching, there is a huge opportunity for the NHS to make further ...

Karin Schwan sat at the head of a wooden table in a room that smelled faintly of hand sanitizer. Printouts about “The ABCs of Diabetes” were on the table in front of her. A man and woman walked into ...

NLS Pharmaceutics Ltd. ("NLS") , a Swiss clinical-stage biopharmaceutical company focused on the discovery and development of innovative therapies for rare and complex central nervous system disorders ...

The literature also provides strong evidence that health education materials are ... and more retinopathy of diabetes. This article describes some current issues in patient education practice ...

Accord BioPharma, Inc., the U.S. specialty division of Intas Pharmaceuticals, Ltd., focused on the development of oncology, immunology, and critical care therapies, is recognizing a critical milestone ...

Germany is widely recognized as one of the leading countries in the pharmaceutical industry boasting a rich history of innovation cutting-edge research and global influence With its well-established i ...

Data from continuous glucose monitors can predict nerve, eye and kidney damage caused by type 1 diabetes researchers have found. That suggests doctors may be able to use data from the devices to help ...

Novo Nordisk's shares plummeted due to disappointing trial results for CagriSema, with patients achieving only 22.7% weight ...

Indeed, just 6% of people with type 2 diabetes attended structured patient education last year, despite more than two-thirds of the patient community admitting they do not understand their condition.

In a new webinar, industry experts explore how innovative technology and direct patient communication are transforming medication adherence in the UK.

Dec. 12, 2024 — Some patients with diabetes develop a serious condition known as diabetic cardiomyopathy, which is slow and cannot be directly attributed to hypertension or other cardiovascular ...

I'm cautious about Novo Nordisk's short-term prospects due to the recent selloff, but see long-term potential with high ...